Journal Mobile Options
Table of Contents
Vol. 73, No. 3, 2004
Issue release date: October 2004
Urol Int 2004;73:212–218

p53 Gene Mutations in Superficial Bladder Cancer

Lorenzo Romero J.G. · Salinas Sánchez A.S. · Giménez Bachs J.M. · Sánchez Sánchez F. · Escribano Martínez J. · Hernández Millán I.R. · Segura Martín M. · Virseda Rodríguez J.A.
aServicio de Urología, Complejo Hospitalario y Universitario de Albacete, y bÐrea de Genética, Facultad de Medicina, Universidad de Castilla La Mancha, Albacete, España

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objectives: To assess the presence of p53 gene mutations in superficial tumors of the urinary bladder (transitional cell carcinoma) and their relationship to classic prognostic factors for cancer recurrence and progression. To analyze the implication of these mutations on the P53 protein structure. Materials and Methods: Observational, cross-sectional study of 90 consecutive patients, 60 with superficial transitional cell carcinoma (pTa and pT1) and 30 without neoplastic disease (control group). Samples of bladder tumor and control normal mucosa were analyzed by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) to detect p53 mutations in exons 5–9. Automatic sequencing was used to characterize the mutations and their effect on the P53 protein was analyzed. Bivariate analysis was used to assess the association with other prognostic factors. Results: PCR-SSCP found no mutations in any control group patient, whereas 38.3% of patients with superficial transitional cell carcinoma had one or more mutations in the exons analyzed. Thirty mutations were sequenced; all were point mutations and 86.67% were considered relevant for the P53 structure. A total of 93.3% of the mutations were located in highly conserved regions and 73.3% in mutational hot spots. The highest cell differentiation grades and pT1 stage were associated with a higher incidence of p53 gene mutations. Previous recurrences and other tumor-related histological variables were not associated with a higher percentage of mutations. Conclusion: Mutations at p53 did not appear in healthy bladder mucosa and were significantly more frequent in pT1 and high-grade (G-II and G-III) tumors. All mutations detected were point mutations and most caused considerable P53 structural abnormalities, implying major repercussions on P53 function. These data suggest that certain p53 mutations may have prognostic value, even though they were not associated with other classic recurrence and tumor progression parameters. Future analyses of the progress of patients with superficial bladder transitional cell carcinoma and mutated p53 will help clarify this aspect.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Knowles MA: La genética del carcinoma de células transicionales: progresión y aplicación clínica potencial. BJU Int 1999;84:412–427.
  2. Keegan PE, Lunec J, Neal DE: p53 and p53-regulated genes in bladder cancer. Br J Urol 1998;82:710–720.
  3. Ðlvarez Kindelán J, López-Beltrán A, Requena Tapia MJ: Biología molecular en el cáncer vesical. Actas Urol Esp 2000;24:604–625.

    External Resources

  4. Lianes P: Biología molecular del cáncer de vejiga; in Vicente J, Chéchile G, Salvador J (eds): Tumores vesicales superficiales. Madrid, Acción Médica, 2000, pp 47–60.
  5. Lu ML, Wicman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z, Dalbagni G, Pohar KS, Yu G, Cordón-Cardó C: Impact of alterations affecting the pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 2002;8:171–179.
  6. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning. A Laboratory Manual. New York, Cold Spring Harbor Laboratory Press, 1989, pp 1134–1225.
  7. Yoshimura I, Kudoh J, Saito S, Tazaki H, Shimizu N: p53 gene mutation in recurrent superficial bladder cancer. J Urol 1995;153:1711–1715.
  8. Rosell-Costa D, García-Foncillas López J, Abad Vivas-Pérez JI, et al: Análisis por secuenciación genómica del oncogén supresor p53 en el carcinoma vesical. Actas Urol Esp 1998;22:552–556.
  9. Gao JP, Uchida T, Wang C, Jiang SX, Matsumoto K, Satoh T, Minei S, Soh S, Kameya T, Baba S: Relationship between p53 gene mutation and protein expression: Clinical significance in transitional cell carcinoma of the bladder. Int J Oncol 2000;16:469–475.
  10. Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW, Stone EM: The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. Genomics 1993;16:325–332.
  11. Cordón-Cardó C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SH, Xu HJ, Reuter E, Benedict WF: Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997;57:1217–1221.
  12. Lynch CF, Cohen MB: Urinary system. Cancel 1995;75:316–329.
  13. Oyasu R, Nan L, Szumel RC, Kawamata H, Hirohashi S: p53 gene mutations in human urothelial carcinomas: analysis by immunohistochemistry and single-strand conformation polymorphism. Mod Pathol 1995;8:170–176.
  14. Phillips HA, Howard GC, Miller WR: p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer. Br J Cancer 2000;82:136–141.
  15. Menéndez López V, Molina Porto R, Alcaraz Asensio A, Gutiérrez del Pozo R, Alcover García JA: Relación entre las recidivas tumorales del gen p53 en los carcinomas transicionales superficiales de vejiga. Actas Urol Esp 2000;24:530–535.
  16. Van Brussel JP, Mickisch GHJ: Prognostic factors in renal cell and bladder cancer. BJU Int 1999;83:902–909.
  17. Gen H, Yamamoto S, Min W, Mitsuhashi M, Murai T, Mori S, Hosono M, Oohara T, Makino S, Wanibuchi H, Fukushina S: p53 and H-ras mutations and microsatellite instability in renal pelvic carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)-nitrosamine: Different genetic alteration from urinary bladder carcinoma. Jpn J Cancer Res 2001;92:1278–1283.
  18. Xu X, Stower MJ, Reid IN, Garner RC, Burns PA: A hot spot for p53 mutation in transitional cell carcinoma of the bladder: Clues to the aetiology of bladder cancer. Cancer Epidemiol Biomarkers Prev 1997;6:611–616.
  19. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997;88:323–331.
  20. Van der Poel HG, Hessels K, Van Leenders GJ, Bussemakers MJ, Schalken JA, Witjes JA, Debruyne FM: Multifocal transitional cell cancer and p53 mutation analysis. J Urol 1998;160:124–125.
  21. Abdel-Fattah R, Challen C, Griffiths TR, Robinson MC, Neal DE, Lunec J: Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: High frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 1998;77:2230–2238.
  22. Lorenzo-Romero JG, Salinas-Sánchez AS, Giménez-Bachs JM, Sánchez-Sánchez F, Escribano-Martínez J, Segura-Martín M, Hernández-Millán IR, Virseda-Rodríguez JA: Prognostic implications of p53 gene mutations in bladder tumors. J Urol 2003;169:492–499.
  23. Liang G, Gonzalgo ML, Salem C, Jones PA: Identification of DNA methylation differences during tumorigenesis by methylation-sensitive arbitrarily primed polymerase chain reaction. Methods 2002;27:150–155.
  24. Greenblatt MS, Beaudet JG, Gump JR, Godin KS, Trombley L, Koh J, Bond JP: Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants. Oncogene 2003;22:1150–1163.
  25. Pogribny IP, Pogribna M, Christman JK, James SJ: Single-site methylation within the p53 promoter region reduces gene expression in a reporter gene construct: Possible in vivo relevance during tumorigenesis. Cancer Res 2000;60:588–594.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50